Replimune is a clinical-stage oncology company developing oncolytic immunotherapies based on engineered herpes simplex virus strains designed to kill tumor cells and stimulate anti-tumor immune responses. Its pipeline centers on intratumoral agents such as RP1 and related constructs, often studied alone or with checkpoint inhibitors. The focus is solid tumors where local injection and systemic immune activation may complement existing immuno-oncology approaches.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -86.7 | — |
| Q3 2025 | 0 | — | -83.1 | — |
| Q4 2025 | 0 | — | -70.9 | — |
| Q1 2026 | 0 | — | -73.2 | — |
| Q2 2026 | 0 | — | -69.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Harrow, Inc. (HROW), Oaktree Specialty Lending Corporation (OCSL), Business First Bancshares, Inc. (BFST), Green Plains Inc. (GPRE), HealthStream, Inc. (HSTM), Mercantile Bank Corporation (MBWM)